1809249-37-3 Usage
General Description
Remdesivir is an antiviral medication that was initially developed to treat Ebola but has since been investigated for its potential use in treating other viral infections, including COVID-19. It works by inhibiting the viral RNA polymerase, which is necessary for the virus to replicate and spread within the body. Clinical trials have shown that remdesivir may help to reduce the severity and duration of symptoms in patients with COVID-19, and it has been granted emergency use authorization by various regulatory agencies. However, further research is still needed to fully understand its safety and efficacy.
Check Digit Verification of cas no
The CAS Registry Mumber 1809249-37-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,8,0,9,2,4 and 9 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1809249-37:
(9*1)+(8*8)+(7*0)+(6*9)+(5*2)+(4*4)+(3*9)+(2*3)+(1*7)=193
193 % 10 = 3
So 1809249-37-3 is a valid CAS Registry Number.
Product Description:
Novel inhibitor of the replication of several taxonomically diverse RNA viruses such as Middle East respiratory syndrome virus, Ebola virus, Lassa fever virus, Junin virus and respiratory syncytial virus, while having low cytotoxicity in a wide-range of cell lines
Remdesivir Properties
Background Information
Remdesivir is a nucleoside analogue, with effective antiviral activity, with EC50s of 74 nM for ARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells.
Remdesivir, also known as GS-5734, is an antiviral drug, a novel nucleotide analog prodrug. It was developed by Gilead Sciences as a treatment for filovirus infections such as Ebola virus disease and Marburg virus, though it has subsequently also been found to show reasonable antiviral activity against more distantly related viruses such as respiratory syncytial virus, Junin virus, Lassa fever virus, and MERS-coronavirus. GS-5734 was rapidly pushed through clinical trials due to the 2013–2016 West African Ebola virus epidemic crisis, eventually being used in at least one human patient despite its early development stage at the time. Preliminary results have been promising, and further clinical trials are planned.
GS-5734 (Remdesivir) is a monophosphoramidate prodrug of adenosine analogue that exhibits antiviral activity against multiple variants of EBOV (EC50=70-140 nM) and other filoviruses (EC50=0.019-1.48 uM) in cell-based assays; suppresses EBOV replication and protects 100% of EBOV-infected animals against lethal disease, ameliorating clinical disease signs and pathophysiological markers.
1809249-37-3Relevant articles and documents
Total synthesis of remdesivir
Kumar Palli, Kishore,Ghosh, Palash,Krishna Avula, Shiva,Sridhara Shanmukha Rao,Patil, Amol D.,Ghosh, Subhash,Sudhakar, Gangarajula,Raji Reddy, Chada,Mainkar, Prathama S.,Chandrasekhar, Srivari
supporting information, (2021/12/20)
Remdesivir, the first drug approved by the FDA to treat COVID-19, is in high demand for patients infected with the SARS-CoV-2 virus. Herein, we report a facile approach minimizing the protecting group manipulations to afford remdesivir in good overall yield.
Preparation method of ridecevir compound
-
Paragraph 0060-0063, (2021/08/07)
The invention belongs to the field of medicinal chemistry, and particularly relates to a novel synthesis and preparation method of a ridecevir compound. (2R, 3R, 4R, 5R)-2-(4-aminopyrrole[2, 1-f][1, 2, 4]triazin-7-yl)-3, 4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-nitrile is taken as an initial raw material, and is subjected to ketal protection, BC protection, resolution, phosphorylation reaction, substitution reaction and deprotection reaction to prepare ridecevir. The method has the advantages of mild and easily-controlled reaction conditions, simple operation, high product yield and high purity, and is suitable for industrial mass production.
ISOMORPHS OF REMDESIVIR AND METHODS FOR SYNTHESIS OF SAME
-
, (2021/06/04)
A new isoform of 2-ethylbutyl (2S)-2-[[[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3/4-dihydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate (Remdesivir) having increased water solubility is disclosed, along with methods